Detection of Acetaldehyde in the Esophageal Tissue among Healthy Male Subjects after Ethanol Drinking and Subsequent L-Cysteine Intake

Hideki Okata,1 Waku Hatta,1 Katsunori Iijima,2 Kiyotaka Asanuma,1 Atsuki Tsuruya,3 Naoki Asano,1 Tomoyuki Koike,1 Shin Hamada,1 Toru Nakayama,3 Atsushi Masamune1,* and Tooru Shimosegawa1,*

1Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
2Department of Gastroenterology and Neurology, Akita University Graduate School of Medicine, Akita, Akita, Japan
3Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Miyagi, Japan

Ethanol is oxidized by alcohol dehydrogenase to acetaldehyde, a recognized carcinogen for the esophagus. However, no previous study has measured the acetaldehyde levels in the esophageal tissue. L-cysteine has been shown to reduce the acetaldehyde levels in the saliva; however, it is unknown whether L-cysteine intake affects the acetaldehyde concentration in the esophageal tissue. The aim of this study was to measure the acetaldehyde concentration in the esophageal tissue after ethanol drinking and evaluate the effect of L-cysteine intake on the acetaldehyde levels in the esophageal tissue. We enrolled 10 male subjects with active acetaldehyde dehydrogenase-2*1/*1 (ALDH2*1/*1) genotype and 10 male subjects with the inactive acetaldehyde dehydrogenase-2*1/*2 (ALDH2*1/*2) genotype, the mean ages of whom were 25.6 and 27.9 years, respectively. In this prospective, single-blind, placebo-controlled study using L-cysteine and placebo lozenges (first and second examination), saliva and blood were collected before and after ethanol drinking. Esophageal tissue was obtained by endoscopic biopsy at 60 minutes after drinking, and the acetaldehyde and ethanol concentrations were measured. The acetaldehyde concentration of the saliva was significantly lower in those taking L-cysteine than in those taking the placebo. Acetaldehyde in the esophageal tissue was detected only in those taking L-cysteine lozenges. There were no correlations between the acetaldehyde concentrations in the esophageal tissue and saliva or blood. In conclusion, we detected acetaldehyde in the human esophageal tissue after ethanol drinking. Unexpectedly, intake of L-cysteine lozenges appears to contribute to detection of acetaldehyde in the esophageal tissue.

Keywords: acetaldehyde; acetaldehyde dehydrogenase; esophageal tissue; L-cysteine; placebo.

Introduction

Alcohol is a major risk factor for esophageal squamous cell carcinoma (ESCC), which represents over 90% of the esophageal cancer in Japan, and acetaldehyde, associated with alcohol intake, was added as a definite carcinogen (a group 1 carcinogen) for the esophagus by the International Agency for Research on Cancer (Secretan et al. 2009). In alcoholic metabolism, alcohol dehydrogenase (ADH) oxidizes alcohol to acetaldehyde, which is further oxidized to acetate by aldehyde dehydrogenase (ALDH) (Zakhari 2006). Thus, single nucleotide polymorphisms of ADH- and ALDH-related genes can modify the reduction of ethanol and acetaldehyde, which would predispose heavy drinkers to cancer (Yokoyama and Omori 2005). Among these, the ADH1B (rs1229984) and ALDH2 (rs671) variations increase the incidence of ESCC, which has been demonstrated by two genome-wide association studies using Japanese cohorts (Cui et al. 2009; Tanaka et al. 2010). Therefore, variations in these genes may affect the ethanol and acetaldehyde concentrations in the esophageal tissue.

The esophageal epithelium is considered to be exposed to carcinogenic acetaldehyde via intrinsic and extrinsic pathways (Ohashi et al. 2015). In the intrinsic pathway of this theory, ethanol, which is absorbed in the upper gastrointestinal tract, is oxidized to acetaldehyde by ADH1B in

Received September 20, 2017; revised and accepted March 2, 2018. Published online April 20, 2018; doi: 10.1620/tjem.244.317.

*Senior authors.

Correspondence: Waku Hatta, Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aobaku, Sendai, Miyagi 980-8574, Japan.
e-mail: waku-style@festa.ocn.ne.jp
the liver, and then the excessive acetaldehyde, which is not oxidized by ALDH2 in the liver, circulates to the esophagus, saliva, and breath (Ohashi et al. 2015). In the extrinsic pathway, acetaldehyde, derived from alcohol beverages, foods, and products by the oral microflora, is directly exposed to the esophageal epithelium (Ohashi et al. 2015). Among these pathways, the locally high exposure to acetaldehyde via saliva is considered to increase the risk of cancer in the upper aerodigestive tract including the esophagus (Brooks et al. 2009; Yokoyama et al. 2010a, 2016). However, it has been difficult to measure the acetaldehyde concentration in the esophageal tissue due to the volatility, rapid metabolism, and low concentrations of acetaldehyde (Heit et al. 2016).

L-cysteine is a semi-essential amino acid that is able to reduce the carcinogenicity of acetaldehyde by forming a direct covalent bond (Salaspuro 2011), the product of which reduces the carcinogenicity of acetaldehyde by forming a 2016).

et al (Heit et al. 1975; Salaspuro et al. 2002, 2006). Preparations that slowly release L-cysteine in the oral cavity have been successfully used to reduce acetaldehyde from the saliva during alcohol consumption and smoking and from the gastric juice of patients with atrophic gastritis (Salaspuro et al. 2002, 2006; Blonigen et al. 2011). In addition, our recent study showed that intake of a slow-release L-cysteine capsule effectively reduced acetaldehyde levels in the gastric juice among active ALDH2*1/*1 homozygotes and inactive ALDH2*1/*2 heterozygotes treated with a proton pump inhibitor (Maemura et al. 2015). Therefore, L-cysteine may also affect the acetaldehyde concentration of the esophageal tissue in each ALDH2 genotype. The aim of this study was to measure acetaldehyde in human esophageal tissue and the effect of L-cysteine on acetaldehyde of the esophageal tissue in each ALDH2 genotype.

**Methods**

*Subject enrollment and study design*

This prospective trial was performed between December 2015 and March 2017. In this study, we planned to enroll 20 healthy male volunteers (10 ALDH2*1/*1 homozygotes and 10 ALDH2*1/*2 heterozygotes). All procedures were carried out at Tohoku University Hospital. The inclusion criteria were male 20 years or older and Helicobacter pylori (H. pylori)-negative confirmed by a 13C-urea breath test (UBIT®, Otsuka Pharmaceutical, Tokyo, Japan) using an infrared spectrophotometer (POCone®, Otsuka Pharmaceutical). The exclusion criteria were 1) current smokers, 2) subjects after resection of gastrointestinal tract or truncal vagotomy, 3) those with ongoing therapy for any disease, 4) those taking drugs except for L-cysteine lozenges during this study, 5) those who could not drink any alcohol, 6) those with a past history of allergy for any drug, 7) those with a past history of liver, kidney or heart disease, and 8) those who were regarded as inappropriate for participating in this study by the researchers.

This was a prospective, single-blind, placebo-controlled trial using slow-release L-cysteine lozenges (Acetium lozenge®, Biohit Oyj, Helsinki, Finland) and identical placebo lozenges in appearance. The study was conducted in accordance with the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee for Human Research at Tohoku University School of Medicine, Sendai, Japan (2015-2-136-1, 2015-2-137-1). All subjects provided written informed consent prior to enrollment in the study. The study was registered at the University Hospital Medical Information (UMIN000019991).

*Study procedure*

A flowchart of the study procedure is shown in Fig. 1. At the study entry (visit 1), the eligibility including ALDH2 and ADH1B genotypes were evaluated in each subject. On two separate occasions using lozenge A (L-cysteine) and lozenge B (placebo) (visit 2 (first examination) and visit 3 (second examination)) at an interval of 1-2 months, the volunteers underwent the following procedures.

On each examination, the volunteers were instructed to refrain from consuming alcohol for 24 hours and food for 12 hours prior to this study, and they came to our institution for this study between 13 and 15 o’clock. Before drinking ethanol, 2 ml each of saliva and blood were collected for subsequent analysis. Then, the subjects drank ethanol (Dehydrated Ethanol; Yoshida Pharmaceutical Company, Tokyo, Japan) (0.5 g/kg body weight) diluted in orange juice to 15% w/vol solution in 10 minutes. This amount of alcohol corresponds to about a moderate dose of alcohol. Subsequently, a
lozenge A or B continued to be taken for 60 minutes so that these lozenges remained present in the mouth of the subjects. At 30 and 60 minutes, 2 ml each of saliva and blood were collected. Patients were asked to stop swallowing saliva for 2 minutes before the saliva was collected. The subjects underwent esophagogastroduodenoscopy (EGD) at 60 minutes after the accumulation of lidocaine viscous oral solution 2% (Xylocaine Viscous 2%; AstraZeneca, Osaka, Japan) in the back of the throat for about 3 to 5 minutes as the pretreatment, and 4 biopsy specimens were taken from the esophagus (5 cm above the esophagogastric junction). Before each biopsy specimen was taken, mucus on the esophageal mucosa was removed by a sufficient amount of water. The endoscopic procedure was performed by an expert endoscopist (WH). These samples were analyzed for the acetaldehyde and ethanol concentrations. The laboratory work was performed so that the investigators were blinded to the subjects’ medical information, and the content of the lozenges was concealed from both subjects and researchers by the coordinator until the end of the trial.

Measurement of acetaldehyde and ethanol concentrations in the saliva, blood and esophageal tissue

A 450-µl sample of saliva was transferred into a headspace vial containing 50 µl of 6 M perchloric acid (PCA) to stop microbial acetaldehyde production and then frozen at −80°C (Hommann et al. 1997). PCA has been shown not to decompose cysteine-acetaldehyde conjugate (Blonigen et al. 2011). Blood was collected from an antecubital vein into a disposable 2.5-ml syringe, and after immediately transferring 1 ml of the blood into a closed vial that had been placed in ice and contained 6 ml of a 0.6 M PCA saline solution, it was instantly deproteinized with a test tube mixer. The precipitated proteins were centrifuged out at 2,300 × g for 15 minutes at 4°C, and a 2-ml sample of the clear supernatant was transferred to a closed headspace vial and stored at −80°C. Four biopsy specimens were immediately transferred into a headspace vial containing 300 µl of 6 M PCA and frozen at −80°C. The samples were stored at −80°C until transfer on dry ice to Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan, for further analysis. The acetaldehyde and ethanol concentrations of each sample were determined by headspace gas chromatography on a VIVax 19091N-233 column (Length: 30 m × 0.25 mm) using a Varian CP 3800/ Tekmar 7000 apparatus (Agilent, CA, USA). In the esophageal tissue, the acetaldehyde and ethanol concentrations were measured by combining four biopsy specimens. Since 0.6M PCA 300 µL was nearly 0.3 g, the ethanol and acetaldehyde concentrations in the esophageal tissue (C) were calculated using the formula:

\[ C = \frac{V}{(\text{weight of the biopsy specimens}}(g) + 0.3 (g)) \]

\[ \text{weight of the biopsy specimens} (g)). \]

Outcomes

The primary outcome in this study was the acetaldehyde concentration of the esophageal tissue after drinking alcohol in taking L-cysteine or placebo lozenges. The secondary outcomes were the acetaldehyde concentrations in the saliva, blood and esophageal tissue in taking L-cysteine or placebo lozenges in each ALDH2 genotype. We also evaluated correlations between the acetaldehyde concentration of the esophageal tissue and that of blood or saliva at 60 minutes after drinking. In addition, we investigated the ethanol concentration of each specimen in taking L-cysteine or placebo lozenges in the

ADH1B genotypes (active ADH1B*1/*2 heterozygotes and highly-active ADH1B*2/*2 homozygotes).

Genotyping of ALDH2 and ADH1B

DNA was extracted from each subject with a DNA Blood Mini Kit (Qiagen, Hilden, Germany). Genotyping for ALDH2 (rs671) and ADH1B (rs1229984) was conducted using TaqMan® Drug Metabolism Genotyping Assay (Thermo Fisher Scientific, Waltham, MA, USA).

L-cysteine and placebo lozenges

Slow-release L-cysteine lozenges contained 3 mg of L-cysteine as the active ingredient. A placebo formulation where L-cysteine was replaced with the same amount of CaHPO₄ was prepared following exactly the same method.

Statistical analysis

Continuous data were presented as means with standard errors of the means (SEM). Student’s t-test was used to compare the two groups. Comparison between categorical variables was performed using the Fisher’s exact test. The mean concentrations of acetaldehyde and ethanol in the saliva and blood were plotted on a graph according to the time after the completion of drinking, and the area under the curve (AUC) from the time before drinking (Time 0) and 30 and 60 minutes after drinking was calculated. For evaluating the relationship between the acetaldehyde concentration of the esophageal tissue and saliva or blood, Pearson’s correlation coefficient (r) was calculated. Data processing and statistical analyses were conducted using SPSS version 20.0 for Windows (SPSS, Chicago, IL, USA). A p value of less than 0.05 was regarded as statistically significant.

Results

Twenty subjects (10 ALDH2*1/*1 homozygotes and 10 ALDH2*1/*2 heterozygotes) completed the whole procedure, and no adverse event occurred during the study. There was no subject with symptoms suspicious for gastroesophageal reflux disease or reflex esophagitis on EGD. The baseline characteristics of the enrolled subjects are shown in Table 1. There was no significant difference in age and body weight between the ALDH2*1/*1 homozygotes and ALDH2*1/*2 heterozygotes. All enrolled subjects continued to take L-cysteine or placebo lozenges during the 60 minutes after drinking. The mean (SEM) numbers of L-cysteine and placebo lozenges taken in the whole procedure were 11.7 (1.0) and 12.3 (1.0), respectively.

Acetaldehyde and ethanol concentrations of the esophageal tissue in taking L-cysteine or placebo lozenges

We evaluated the acetaldehyde and ethanol concentrations of the esophageal tissue in taking L-cysteine or placebo. Typical chromatograms of acetaldehyde and ethanol in the samples and esophageal tissues are shown in Fig. 2A, B, respectively. In these chromatograms, prominent peaks corresponding to acetaldehyde and ethanol were observed. Among cases taking L-cysteine, we could detect acetalde-
Hyde from the esophageal tissue in 5 cases, comprising 3 \( ALDH2^*/1/1 \) homozygotes and 2 \( ALDH2^*/1/2 \) heterozygotes, whereas acetaldehyde in the esophageal tissue did not appear in any cases taking the placebo (Fig. 3A, B). There was no correlation in the acetaldehyde concentration between the esophageal tissue and saliva or blood at 60 minutes \((r = -0.091, p = 0.58 \text{ and } r = -0.12, p = 0.46, \text{ respectively})\).

Concerning the ethanol concentration of the esophageal tissue in each \( ADH1B \) genotype was shown in Fig. 3C, D. There was no significant difference between those taking L-cysteine and the placebo in \( ADH1B^*/2/2 \) homozygotes. In taking the placebo, the ethanol concentration of the esophageal tissue was significantly higher than that of the saliva and blood at 60 minutes \((p < 0.001 \text{ and } p = 0.001, \text{ respectively})\).

**Acetaldehyde and ethanol concentrations of the saliva in taking L-cysteine or placebo lozenges**

In taking the placebo, the AUC for the acetaldehyde

---

**Table 1. Baseline characteristics of the enrolled subjects.**

<table>
<thead>
<tr>
<th></th>
<th>( ALDH2^*/1/1 ) (n = 10)</th>
<th>( ALDH2^*/1/2 ) (n = 10)</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years (SEM)</td>
<td>25.6 (1.2)</td>
<td>27.9 (7.9)</td>
<td>0.39</td>
</tr>
<tr>
<td>Mean body weight, kg (SEM)</td>
<td>64.3 (2.4)</td>
<td>63.3 (2.3)</td>
<td>0.77</td>
</tr>
<tr>
<td>Mean number of L-cysteine lozenges, n (SEM)</td>
<td>10.5 (1.2)</td>
<td>12.8 (1.4)</td>
<td>0.24</td>
</tr>
<tr>
<td>Mean number of placebo lozenges, n (SEM)</td>
<td>11.6 (1.2)</td>
<td>13.0 (1.4)</td>
<td>0.48</td>
</tr>
</tbody>
</table>

**ADH1B genotype**

<table>
<thead>
<tr>
<th></th>
<th>( ADH1B^*/2/2 ), n</th>
<th>( ADH1B^*/1/2 ), n</th>
</tr>
</thead>
<tbody>
<tr>
<td>( ADH1B^*/2/2 ), n</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>( ADH1B^*/1/2 ), n</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

**ALDH, acetaldehyde dehydrogenase; SEM, standard errors of the means; ADH, alcohol dehydrogenase.**
concentration in the saliva tended to be higher in \textit{ALDH2}*/1/*2 heterozygotes than in \textit{ALDH2}*/1/*1 homozygotes (\(p = 0.21\)). In addition, a higher AUC for the ethanol concentration in \textit{ADH1B}*/1/*2 heterozygotes was shown (\(p = 0.13\)). In the \textit{ALDH2}*/1/*1 homozygotes, the acetaldehyde concentration of the saliva in taking L-cysteine was lower than that in taking the placebo at 30 and 60 minutes after drinking (Fig. 4A). The AUC for the acetaldehyde concentration in the saliva was significantly lower in taking L-cysteine than in taking the placebo (1.7 ± 0.9 (\(\mu\text{M·h, mean ± SEM}\)) vs. 9.7 ± 1.5, \(p = 0.002\)). In addition, similar results in the AUC appeared in the \textit{ALDH2}*/1/*2 heterozygotes (7.3 ± 1.7 vs. 12.8 ± 1.8, \(p = 0.036\)) (Fig. 4B).

Regarding the ethanol concentration of the saliva (Fig. 4C, D), the AUC in the \textit{ADH1B}*/2/*2 homozygotes was significantly lower in taking L-cysteine than in taking the placebo (8.7 ± 0.8 (\(\text{mM·h, mean ± SEM}\)) vs. 11.2 ± 0.8, \(p = 0.022\)).

\textit{Acetaldehyde and ethanol concentrations of the blood in taking L-cysteine or placebo lozenges}

In taking the placebo, the AUC for the ethanol concentration was significantly higher in \textit{ADH1B}*/1/*2 heterozygotes than in \textit{ADH1B}*/2/*2 homozygotes (\(p = 0.045\)), although that for the acetaldehyde concentration in the blood was not different between the two \textit{ALDH2} genotypes. The acetaldehyde concentrations of the blood showed no significant differences in the AUC between those taking L-cysteine and the placebo, regardless of the \textit{ALDH2} genotypes (Fig. 5A, B). Concerning the ethanol concentration in the blood (Fig. 5C, D), no significant difference in the AUC was shown between those taking the two kinds of lozenges in \textit{ADH1B}*/2/*2 homozygotes.

\textbf{Discussion}

In this study, we firstly detected acetaldehyde in the esophageal tissue. In addition, although the acetaldehyde concentration of the saliva was significantly lower in those taking L-cysteine lozenges than in those taking the placebo in both \textit{ALDH2} genotypes, acetaldehyde of the esophageal tissue appeared only in those taking L-cysteine lozenges. Acetaldehyde associated with alcohol intake was regarded as a definite carcinogen (a group 1 carcinogen) for...
the esophagus by the International Agency for Research on Cancer (Secretan et al. 2009). However, its direct measurement in the tissue has remained difficult because of its low levels, high volatility, and rapid metabolism by ALDH (Eriksson et al. 1979). Since acetaldehyde has been shown to interact with DNA to form DNA adducts, such as \( N^2 \)-ethylidene-2′-deoxyguanosine (Yukawa et al. 2012), \( N^2 \)-ethyl-2′-deoxyguanosine (Matsuda et al. 2006) and 1, \( N^2 \)-propano-2′-deoxyguanosine (Yu et al. 2010), a previous study dealing with acetaldehyde in the esophageal tissue used a DNA adduct (\( N^2 \)-ethyl-2′-deoxyguanosine) as a marker for acetaldehyde exposure (Amanuma et al. 2015). Meanwhile, the acetaldehyde concentrations in the human saliva, blood, breath, and gastric juice have been successfully measured (Vakevainen et al. 2001; Muto et al. 2002; Salaspuro et al. 2002; Visapaa et al. 2004; Yokoyama et al. 2008, 2010b; Maejima et al. 2015). In our previous study, for accurately measuring the acetaldehyde concentration, the obtained saliva and gastric juice were transferred into a headspace vial containing PCA to stop microbial acetaldehyde production, and the samples were immediately deep frozen and stored at \(-80^\circ C\) to prevent volatilization (Maejima et al. 2015). In this study, we used this technique until transfer on dry ice to the headspace gas chromatography for measuring the acetaldehyde concentration of the esophageal tissue. In addition, for avoiding the possibility of measuring the acetaldehyde of mucus on the esophageal tissue, mucus on the esophageal mucosa was removed by a sufficient amount of water before taking each biopsy. As a result, we could detect acetaldehyde of the esophageal tissue in 5 cases. To our knowledge, this is the first study measuring the acetaldehyde concentration in the human esophageal tissue, which is one of the clinical implications in this study. This direct measurement of acetaldehyde in the esophageal tissue would contribute to exploring how the acetaldehyde level in the esophageal tissue correlates with DNA damage and carcinogenesis in future studies.

Meanwhile, we found many cases in which acetaldehyde was not detected in the esophageal tissue. In particular, acetaldehyde of the esophageal tissue was not detected in all cases taking the placebo. Several factors such as technical problems and volatilization may have affected the acetaldehyde concentration in the esophageal tissue. Although we believe this study result is reliable because it was performed in a blind manner, a further validation study is needed to confirm our results. In addition, it is desirable to measure parallel samples and calculate the mean value to minimize variations in the samples, although it was ethi-
Detecting Acetaldehyde in the Human Esophageal Tissue

Detecting Acetaldehyde in the Human Esophageal Tissue was technically difficult in this study. Furthermore, one of the reasons for the many cases of undetected acetaldehyde may be that the small concentration of acetaldehyde was below the measurable concentration in the headspace gas chromatography. Recently, Heit et al. (2016) demonstrated the feasibility of headspace gas chromatography mass spectrometry (GC-MS) by measuring the ethanol and acetaldehyde concentrations in the low µM range in murine neuronal tissue. Thus, the headspace GC-MS methods may enable the measurement of acetaldehyde of the esophageal tissue with higher sensitivity.

Regarding the source of acetaldehyde, the esophageal epithelium is exposed to carcinogenic acetaldehyde via an intrinsic and extrinsic pathway (Ohashi et al. 2015). Among these pathways, direct exposure of acetaldehyde, derived from saliva, alcohol beverages, and so on, to the esophageal epithelium has been considered to be the main source of acetaldehyde in the esophageal tissue. Thus, the headspace GC-MS methods may enable the measurement of acetaldehyde of the esophageal tissue with higher sensitivity.

In the present study, we also found ethanol in the esophageal tissue in all cases and there was no significant difference in the ethanol concentration between those taking L-cysteine and the placebo in ADH1B*2/*2 homozygotes. In the esophagus, ADH activity was reported to be approximately 4-fold that of stomach enzymes (Yin et al. 1993). On the other hand, it is controversial whether ALDH2 protein is produced in the esophagus (Yin et al. 1993; Morita et al. 2005; Amanuma et al. 2015). Among these reports, Yin et al. (1993) reported that the ALDH activity in the esophagus was 20% of that in the stomach. However, Amanuma et al. (2015) demonstrated that ALDH2 production is induced by acetaldehyde in esophageal keratinocytes and

---

Fig. 5. Acetaldehyde and ethanol concentrations in the blood in taking L-cysteine or placebo lozenges.
A. Acetaldehyde concentration in ALDH2*1/*1 homozygotes (n = 10).
B. Acetaldehyde concentration in ALDH2*1/*2 heterozygotes (n = 10).
C. Ethanol concentration in ADH1B*2/*2 homozygotes (n = 18).
D. Ethanol concentration in ADH1B*1/*2 heterozygotes (n = 2).
There was no significant difference in the AUC for the acetaldehyde concentration between those taking L-cysteine and the placebo lozenges, regardless of the ALDH2 genotype. Similarly, no significant difference in the AUC for the ethanol concentration of blood was shown between the two kinds of lozenges in ADH1B*2/*2 homozygotes. Statistical analysis was not performed in part due to the small number of samples.

ALDH, acetaldehyde dehydrogenase; ADH, alcohol dehydrogenase; AUC, area under the curve.

---

study revealed that acetaldehyde in the esophageal tissue appeared only in taking L-cysteine lozenges; in contrast, the acetaldehyde concentration of the saliva was significantly lower in taking L-cysteine lozenges than in taking the placebo. In addition, similar results were shown in both ALDH2 genotypes. Although we detected acetaldehyde of the esophageal tissue in a small number of cases, this result is significant because this study was performed in a blind manner. Therefore, there is a possibility that acetaldehyde of the saliva may play a limited role in the acetaldehyde concentration of the esophageal tissue.
that ALDH2 plays a protective role against acetaldehyde-derived DNA damage in esophageal squamous epithelium. Thus, these results in the previous studies and our data suggest that there may be a pathway by which ethanol is metabolized into acetaldehyde, which is further metabolized into acetic acid, in the esophagus, which may affect the acetaldehyde concentration of the esophageal tissue. However, for confirming this hypothesis, further study is needed.

We can raise two strengths in this study. First, this is a prospective, single-blind, placebo-controlled trial using L-cysteine and placebo lozenges, which reduced the bias. In addition, the biopsy specimens of the esophageal tissue were taken by an expert endoscopist who was blinded to any clinical information of the subjects in the same manner, resulting in minimal variance in the sizes of the biopsy specimens. In fact, the weight of the biopsy specimens was similar among the subjects. Therefore, the results related to the acetaldehyde and ethanol concentrations of the esophageal tissue in this study are likely reliable.

This study includes several limitations. First, the dose of L-cysteine and the placebo lozenges depended on the subjects. In this study, the subjects were advised that the intake of L-cysteine lozenges appears to contribute to detecting acetaldehyde in the esophageal tissue. Finally, we cannot avoid the artefactual formation of acetaldehyde from ethanol in measuring the acetaldehyde concentration of the blood and saliva at the time immediately after drinking. Third, variation of microbes and fungii in each subject may have affected the acetaldehyde concentrations in the blood and saliva at the time immediately after drinking. Instead, intake of L-cysteine lozenges appears to contribute to detection of acetaldehyde in the esophageal tissue.

In conclusion, we firstly detected acetaldehyde in human esophageal tissue. In addition, continuous taking of L-cysteine lozenges after drinking may have little effect in reducing acetaldehyde from the esophageal tissue. Therefore, for confirming this hypothesis, further study is needed.

Acknowledgments
This study was supported in part by JSPS KAKENHI (15K19308, 15K08945, 17K15917).

Conflict of Interest
The authors declare no conflict of interest.

References


